T he complex pathophysiology of type 2 diabetes (T2D) arises from cell-autonomous consequences of insulin resistance that can propagate among heterologous tissues through dysregulated lipid flux [1] [2] [3] , bile acids or circulating intermediary metabolites 4 , as well as dysregulated production and secretion of cytokines, adipokines and hepatokines 3, 5, 6 . Although T2D is characterized by systemic insulin resistance, disruption of hepatic insulin signaling alone recapitulates many aspects of T2D 7 , including enhanced endogenous glucose production 8 . Even though endogenous glucose production includes renal and intestinal contributions 9 , it is mainly a function of hepatocytes. Hepatic glucose production (HGP) is suppressed directly by insulin via inhibition of hepatic glycogenolysis and gluconeogenesis, and indirectly by insulin-mediated suppression of adipose tissue lipolysis, glucagon secretion and neuronal signals . In addition to dysregulated hepatic metabolism and mitochondrial dysfunction 13 , LDKO mice develop systemic metabolic disease-including glucose intolerance, hyperinsulinemia and dysregulated energy homeostasis 12, 14 . Remarkably, hepatic and systemic dysregulation is largely corrected upon further genetic deletion of hepatic Foxo1 in the LDKO mice-despite continued persistent and complete hepatic insulin resistance 12, 13 . These findings are confirmed and extended by others using compound hepatic-specific IRK; FoxO1-knockout or Akt1; Akt2; FoxO1-knockout mice 1, [15] [16] [17] . The normalization of HGP in these models owes, at least partially, to the re-sensitization of white adipose tissue (WAT) to insulin, which indirectly reduces hepatic gluconeogenesis by decreasing substrate availability and downregulating hepatic pyruvate carboxylase activity 1 . In models of complete hepatic insulin resistance (including LTKO mice), genetic disruption of hepatic Foxo1 substantially normalizes the expression of hundreds of dysregulated hepatic genes 12, 16 . Within such mice, FoxO1-dependent gene expression, or metabolic signals generated in hepatocytes, could reasonably contribute to dysregulation of peripheral insulin sensitivity and promote the delivery of metabolic intermediates to the liver-including excess glycerol and free fatty acids (FFAs) from adipose tissue 3 . Thus, though it fails to restore hepatic insulin signaling per se, disrupting hepatic FoxO1 in LDKO mice (that is, LTKO mice) and similar models effectively restores glucose tolerance 12, 15, 17, 18 . Regardless, how hepatic FoxO1 disruption might prevent the manifestation of peripheral insulin resistance has remained unclear.
, as well as dysregulated production and secretion of cytokines, adipokines and hepatokines 3, 5, 6 . Although T2D is characterized by systemic insulin resistance, disruption of hepatic insulin signaling alone recapitulates many aspects of T2D 7 , including enhanced endogenous glucose production 8 . Even though endogenous glucose production includes renal and intestinal contributions 9 , it is mainly a function of hepatocytes. Hepatic glucose production (HGP) is suppressed directly by insulin via inhibition of hepatic glycogenolysis and gluconeogenesis, and indirectly by insulin-mediated suppression of adipose tissue lipolysis, glucagon secretion and neuronal signals 8 .
The proteins insulin receptor substrate 1 (Irs1) and Irs2 link the activated insulin receptor kinase (IRK) to the phosphatidylinositol-3-OH kinase (PI3K)-Akt cascade, which regulates the expression of hundreds of hepatic genes by inactivating the Forkhead box O (FoxO) family of transcription factors 10, 11 . We previously investigated the consequences of hepatic Irs1 and 12 . In addition to dysregulated hepatic metabolism and mitochondrial dysfunction 13 , LDKO mice develop systemic metabolic disease-including glucose intolerance, hyperinsulinemia and dysregulated energy homeostasis 12, 14 . Remarkably, hepatic and systemic dysregulation is largely corrected upon further genetic deletion of hepatic Foxo1 in the LDKO mice-despite continued persistent and complete hepatic insulin resistance 12, 13 . These findings are confirmed and extended by others using compound hepatic-specific IRK; FoxO1-knockout or Akt1; Akt2; FoxO1-knockout mice 1, [15] [16] [17] . The normalization of HGP in these models owes, at least partially, to the re-sensitization of white adipose tissue (WAT) to insulin, which indirectly reduces hepatic gluconeogenesis by decreasing substrate availability and downregulating hepatic pyruvate carboxylase activity 1 . In models of complete hepatic insulin resistance (including LTKO mice), genetic disruption of hepatic Foxo1 substantially normalizes the expression of hundreds of dysregulated hepatic genes 12, 16 . Within such mice, FoxO1-dependent gene expression, or metabolic signals generated in hepatocytes, could reasonably contribute to dysregulation of peripheral insulin sensitivity and promote the delivery of metabolic intermediates to the liver-including excess glycerol and free fatty acids (FFAs) from adipose tissue 3 . Thus, though it fails to restore hepatic insulin signaling per se, disrupting hepatic FoxO1 in LDKO mice (that is, LTKO mice) and similar models effectively restores glucose tolerance 12, 15, 17, 18 . Regardless, how hepatic FoxO1 disruption might prevent the manifestation of peripheral insulin resistance has remained unclear.
Comprehensive analyses of gene expression reveal various genes encoding secreted proteins that are expressed in the human liver (socalled hepatokines), some of which might affect glucose and lipid metabolism 5, 6, 19 . We hypothesized that FoxO1-dependent dysregulation of hepatokines in the LDKO liver might promote peripheral insulin resistance-and substantially underlie the restoration of metabolic homeostasis in LTKO mice. In this report, we use the LDKO and LTKO mice to identify follistatin (Fst)-best known for its modulation of transforming growth factor-β (TGF-β ) superfamily members 20, 21 -as a key FoxO1-dependent hepatokine that can dysregulate WAT insulin sensitivity and hepatic gene expression to propagate systemic metabolic disease during hepatic insulin resistance. Supplementary Fig. 1b ), a result that is similar to mice lacking the adipocyte insulin receptor (FIRKO mice) 22 or adipocyte Akt1 and Akt2 (ref. 23 ). Thus, dysregulation of the Irs1/2-PI3K-Akt cascade in WAT alone was insufficient to impair systemic glucose homeostasis during the intraperitoneal glucose tolerance test (GTT).
Results

Hepatic Foxo1 is required for excess HGP and glucose intolerance during hepatic insulin resistance. Lipolysis of WAT
Inactivating hepatic follistatin alleviates hyperglycemia
To understand the requirement of hepatic insulin signaling for systemic glucose homeostasis, we investigated glucose tolerance and HGP in LDKO and LTKO mice 12 . As shown previously, LDKO mice developed glucose intolerance, which was corrected in LTKO mice ( Supplementary Fig. 1b,c) . As excess HGP contributes to systemic glucose dysregulation, we used a hyperinsulinemic-euglycemic clamp to compare HGP in LDKO and LTKO mice. The glucose infusion rate (GIR), which is required to maintain euglycemia during insulin infusion (4 mU per kg per min), was significantly greater in Cntr mice than in LDKO mice (Fig. 1a) ; however, the GIR was normal in LTKO mice, despite the absence of hepatic Irs1 and Irs2 (Fig. 1b) . Moreover, insulin failed to suppress HGP in LDKO mice, whereas HGP was suppressed normally by insulin in LTKO mice (Fig. 1c,d ). Thus, hepatic insulin signaling was dispensable for glucose tolerance and the regulation of HGP when hepatic FoxO1 was inactivated.
Hepatic FoxO1 dysregulates WAT insulin signaling. Normal suppression of HGP in LTKO mice suggested that insulin indirectly suppressed HGP through its effects on WAT or other tissues. To investigate insulin signaling in the extrahepatic tissues of LDKO mice, we measured Akt phosphorylation on serine 473 and threonine 308 (pS473 Akt and pT308 Akt ) in the skeletal muscle, epigonadal WAT (eWAT), inguinal WAT (iWAT) and brown adipose tissue (BAT) upon completion of the hyperinsulinemic-euglycemic clamp. Compared with Cntr mice, LDKO mice showed reduced levels of pS473
Akt and pT308 Akt in the eWAT, iWAT and BAT, with insignificant changes in skeletal muscle ( Supplementary Fig. 1d-f ). By contrast, pS473
Akt and pT308 Akt phosphorylation levels were normal in the eWAT and the iWAT isolated from LTKO mice ( Supplementary  Fig. 1g-i) . Moreover, in contrast to Cntr mice, insulin-stimulated Irs1-p110 PI3K complex formation was significantly decreased (by 49%) in the eWAT of LDKO mice, whereas the association was normal in the eWAT of LTKO mice (Fig. 1e) . These results suggest that hepatic FoxO1 promoted WAT insulin resistance in LDKO mice.
To determine whether adult-onset hepatic insulin resistance promoted FoxO1-dependent WAT insulin resistance, LDKO mice were created acutely by infecting Irs1 ; Cre AAV-TBG mice displayed low levels of hepatic Irs1 and Irs2 proteins and developed glucose intolerance ( Supplementary Fig. 2a,b) . Conversely, glucosetolerant adult LTKO mice infected with FoxO1
AdV (adenovirus encoding FoxO1) developed glucose intolerance ( Supplementary  Fig. 2c,d ). Consistently, insulin-stimulated Irs1-p110 PI3K complex formation decreased significantly in the eWAT of both Irs1
; Cre AAV-TBG mice and LTKO FoxO1 AdV mice (Fig. 1f,g ). Thus, hepatic FoxO1 promoted adipose tissue insulin resistance following the acute loss of hepatic insulin signaling.
Next, we investigated the activation state of hormone-sensitive lipase (HSL) in the eWAT by measuring the phosphorylation of this protein. Compared with Cntr mice, pS660HSL levels were higher in the eWAT of LDKO mice during fasting and insulin-stimulated conditions; however, pS660HSL levels were indistinguishable in the eWAT of insulin-stimulated LTKO mice and their litter-matched controls (Cntr3) (Supplementary Fig. 2e ). Consistent with these results, insulin failed to suppress circulating FFAs in LDKO mice but suppressed FFAs normally in LTKO mice ( Supplementary  Fig. 2f,g ). Moreover, compared to control mice, H&E staining revealed smaller adipocytes in the eWAT from LDKO mice and LTKO FoxO1
AdV mice ( Supplementary Fig. 2h ). These results suggest that hepatic FoxO1 indirectly suppressed Irs1-PI3K-Akt-HSL signaling in the eWAT of LDKO mice.
Finally, we compared the RNA expression profiles of the eWAT obtained from Cntr and LDKO mice, and Cntr3 and LTKO mice. Compared to the controls, the expression of 82 genes decreased and 83 genes increased more than 2-fold in the eWAT of LDKO mice, most of which returned to normal expression in the eWAT of LTKO mice ( Supplementary Fig. 2i and Supplementary Table 1) . These results suggest that disruption of hepatic Irs1 and Irs2 promotes FoxO1-dependent gene expression changes in the eWAT, which might integrate with hepatic dysfunction to dysregulate systemic glucose homeostasis. Indeed, Cre AAV-TBG -mediated deletion of hepatic Irs1 and Irs2 in the FDKO mice caused fasting hyperglycemia and severe glucose intolerance (Fig. 1h,i) , suggesting that hepatic and adipose insulin resistance together synergistically disrupt glucose homeostasis ( Supplementary Fig. 2j ).
Identification of FoxO1-dependent hepatokines in LDKO mice.
Previous work suggests that inflammatory cytokines might dysregulate systemic glucose metabolism 24 . We measured the circulating concentrations of several cytokines in LDKO and LTKO mice, including tumor necrosis factor-α (TNF-α ), interleukin-6 (IL-6), IL-1β , IL-2, IL-4, IL-5, chemokine (C-X-C motif) ligand 1 (CXCL1; also known as KC) and C-C motif chemokine ligand 3 (CCL3; also known as MIP1-α ); however, only IL-6 displayed significant FoxO1-dependent elevation ( Supplementary Fig. 3a-h ). We generated LDKO IL-6 -/-mice to test whether IL-6 contributed to glucose intolerance and WAT insulin resistance; however, glucose intolerance was not normalized in LDKO IL-6 -/-mice compared to Cntr IL-6 -/-mice ( Supplementary Fig. 3i ). Furthermore, insulin-stimulated formation of the Irs1-p110 PI3K complex remained low in the eWAT from LDKO IL-6 -/-mice ( Supplementary Fig. 3j ). We conclude that the elevated levels of IL-6 were not responsible for the dysregulated glucose homeostasis and eWAT insulin resistance in LDKO mice.
To test whether serum from LDKO mice contains hepaticderived circulating factors that modulate peripheral insulin action, cultured 3T3-L1 adipocytes were treated for 24 h with 5% mouse serum obtained from LDKO or Cntr mice and then incubated briefly with insulin. Serum from the LDKO mice significantly reduced (by 51%) the formation of the Irs1-p110 PI3K complex, whereas heat-inactivated serum had no effect (Fig. 2a) . These data indicate that heat-labile circulating protein (or proteins) or other factor (or factors) in LDKO mice might inhibit insulin signaling in adipose tissues.
To find hepatokines that promote systemic insulin resistance in LDKO mice, we used published Affymetrix microarray data to identify the liver genes that were higher or lower (≥ 3-fold, false discovery rate (FDR) < 0.05) in LDKO mice than in Cntr mice (Array Express accession no. E-MEXP-1649) 12 . We further selected the genes that changed in LDKO mice but were expressed normally in LTKO mice and filtered this subset against a curated list of secreted proteins that was confirmed by Ingenuity Pathway Analysis. This strategy revealed 19 putative hepatokines that were ≤ 3-fold lower and 66 that were ≥ 3-fold higher in LDKO mice (Fig. 2b,c) . Some of these hepatokines might have effects on peripheral metabolism-including lower levels of insulin-like Articles NaTUre MeDiciNe growth factor-1 (Igf1; which mediates body growth), or higher levels of lipoprotein lipase (Lpl; which facilitates triglyceride uptake), follistatin (Fst; which inhibits TGF-β -Smad signaling 25 ) or insulin-like growth factor (Igf) binding protein 1 (Igfbp1; which inhibits Igf1 signaling). Thus, we infected wild-type (WT) mice maintained on a high-fat diet (HFD) with AAV TBG vectors encoding several candidate hepatokines or a control GFP AAV-TBG . The first cohort-including growth hormone receptor (Ghr), glutathione peroxidase 3 (Gpx3), serine peptidase inhibitor, clade B, member 6a (Serpinb6a), myelin protein zero-like 1 (Mplz1) or neurotrophin 3 (Ntf3)-had no effects on fasting glucose levels, insulin levels, glucose tolerance or insulin tolerance ( Supplementary Fig. 4a-f ). In the second cohort, leukocyte elastase inhibitor A (Serpinb1a) and serum amyloid a4 (Saa4) decreased glucose levels without an effect on serum insulin levels, whereas Igf1 and inhibin E (Inhbe) increased serum insulin levels without effects on glucose levels (Fig. 2d,e) . However, Fst315 (circulating Fst) increased circulating glucose and insulin levels, and the homeostatic model assessment of insulin resistance (HOMA-IR) suggested that Fst315 promoted systemic insulin resistance (Fig. 2d-f ). Fst315 also promoted significant insulin resistance during the insulin tolerance test (Fig. 2g ). Most of the tested hepatokines had an insignificant effect on glucose tolerance; however, Fst315 impaired glucose tolerance significantly, and Lpl significantly improved glucose tolerance (Fig. 2h,i) . Finally, we confirmed the expression of the virusencoded hepatokine genes in the liver by quantitative PCR (qPCR; Supplementary Fig. 4g,h ). Fst315
AAV-TBG infection of Cntr mice on a HFD increased circulating Fst315 levels by 23-fold (Fig. 2j) . 
Irs2
L/L mice 2 weeks after Cre AAV-TBG or GFP AAV-TBG injection; the inset shows the AUC (n = 5-6). Data were analyzed by one-way ANOVA (c-e,h,i) and unpaired Student's t-test (a-d,f,g). All data are presented as the mean ± s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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To determine whether a more physiological 2-fold increase circulating Fst levels could dysregulate glucose tolerance, C57BL6 mice on a HFD for 2 months were infected with a lower dose of Fst315 AVG-TBG or control GFP AAV-TBG . Ten days after Fst315 AVG-TBG infection, circulating Fst levels were 2.2-fold higher than in controls, which still elevated fasting glucose levels and impaired glucose tolerance 
S100a13
Lrch3 Prelp Several of these secreted proteins that seemed likely to have effects on peripheral metabolism (marked with a black star) were selected for functional screening in mice. d-i, Five-week-old C57BL6 mice were challenged with a HFD (45% fat) for 2 months, then infected with GFP AAV-TBG or hepatokine AAV-TBG (2 × 10 11 genome copy per mouse) encoding the indicated genes. Fasting blood glucose (d) and fasting serum insulin (e) were measured 1 week after infection and used to calculate HOMA2-IR (f) as a measure of systemic insulin resistance (n = 5-10). Insulin tolerance tests were performed 4 weeks after infection with GFP AAV-TBG or hepatokine AAV-TBG and summarized by the AUC (n = 4-10) (g). GTTs were performed 1 week after AAV infection (h) and summarized by the AUC (n = 4-10) (i). j, Fasting serum Fst levels measured 4 weeks after infection of HFD-fed C57BL6 mice with Fst315 AAV-TBG or GFP AAV-TBG (n = 5). Data were analyzed by two-way ANOVA (h), one-way ANOVA (d-g,i) and unpaired Student's t-test (a,j). Data are reported as the mean ± s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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NaTUre MeDiciNe (Supplementary Fig. 4i-k) . Together, these results suggest that Fst315 contributed, at least in part, to the hepatic FoxO1-dependent WAT insulin resistance and glucose intolerance in LDKO mice.
FoxO1 regulates Fst expression in LDKO mice. Two Fst isoforms are generated by alternative mRNA splicing, including membranebound (autocrine) Fst288 and the longer circulating (endocrine) Fst315 (ref. 21 ). Compared to fed Cntr mice, hepatic Fst mRNA (total and Fst315) and circulating Fst protein levels were 2-fold higher during fasting and 6-fold higher during streptozotocin-induced type 1 diabetes ( Supplementary Fig. 5a -e). This pattern of expression was consistent with previous work showing that hepatic Fst is upregulated by an elevated glucagon/insulin ratio 25 . Although this ratio was relatively low in LDKO mice-glucagon levels were elevated 4-fold, whereas insulin levels were elevated 20-fold ( Supplementary  Fig. 5f ,g)-the LDKO liver fails to respond to insulin, so the effect of glucagon might be exaggerated. Compared to the Cntr liver, the levels of mRNA in the LDKO liver encoding Fst288 and Fst315 increased 10-fold and 30-fold, respectively (Fig. 3a) . Moreover, the concentration of circulating Fst in fasted LDKO mice increased 20-fold, and immunostaining revealed more Fst protein in liver sections (Fig. 3b,c) . Fst mRNA levels were also higher in the liver of hepatocyte-specific insulin receptor knockout mice (LIRKO mice), confirming that hepatic insulin signaling suppressed Fst expression ( Supplementary Fig. 5h ). Consistent with these results, serum Fst levels were ~2-fold higher in genetically obese mice (ob/ob) or in Cntr mice fed a HFD ( Supplementary Fig. 5i ), which can be expected to impair glucose tolerance ( Supplementary Fig. 4j ).
Circulating and hepatic Fst levels were normal in the LTKO mice, suggesting that FoxO1 promoted its expression during hepatic insulin resistance (Fig. 3a,b) . Moreover, infection of primary hepatocytes from C57BL6 mice with shFoxO1
AdV decreased the levels of glucagon-stimulated Fst, compatible with a role for FoxO1 in stimulation by a high glucagon/insulin ratio (Fig. 3d) . Consistent with these results, FoxO1
AdV increased Fst mRNA levels and protein concentration in cultured hepatocytes and increased the concentration of Fst secreted into the medium (Fig. 3e ). By contrast, infection with shFoxO1
AdV decreased Fst mRNA levels and the concentration of Fst protein in cultured hepatocytes and in the medium (Fig. 3f) .
Finally, we used chromatin immunoprecipitation (ChIP) with a FoxO1 antibody to determine whether FoxO1 binds directly to the Fst promoter. By comparison with strong FoxO1 binding to the Pck1 promoter (positive control) or weak background binding to the Gapdh promoter (negative control), FoxO1 bound significantly between − 525 and − 2,175 of the Fst promoter (Fig. 3g ). These regions contain several consensus FoxO1-binding sites that are homologous among human, mouse and rat, supporting the hypothesis that nuclear FoxO1 is an important regulator of Fst expression ( Supplementary Fig. 5j ).
Bariatric surgery reduces Fst in obese individuals with diabetes.
Previous reports show that plasma Fst levels are elevated in individuals with T2D 25, 26 . To investigate the relationship between glucose dysregulation and Fst in humans, we measured circulating Fst concentration in a group of obese individuals with diabetes (body mass index: 45.5 ± 3, hemoglobin A1c (HbA1c (%)): 8.4 ± 1) before and after treatment by Roux-en-Y gastric bypass surgery (RYGB) (Supplementary Table 2 ).
Six months after RYGB, the HbA1c percentage decreased significantly to 6%, confirming a beneficial effect on glycemic control (Fig. 3h) . Moreover, the serum Fst concentration correlated positively with the declining HbA1c percentage (Pearson correlation: r = 0.5977, P = 0.0088), as it decreased significantly, by 48%, 6 months after RYGB (Fig. 3i) . Importantly, the Fst concentration changed within the biologically active range ( Supplementary Fig. 4i-k) .
Thus, the beneficial effect of RYGB might be related, at least in part, to reduced circulating Fst levels. ). Compared to the control null AAV-TBG vector, sgFst2 AAV-TBG significantly reduced total hepatic and circulating Fst levels by 2-fold, whereas sgFst1 AAV-TBG produced an intermediate effect that did not reach significance (Fig. 4a,b) . Consistent with the differential reduction of Fst levels in the liver using these two different guide RNAs, glucose tolerance reached the normal range in LDKO sgFst2 AAV-TBG mice, whereas LDKO sgFst1 AAV-TBG mice displayed an intermediate but insignificant reduction (Fig. 4c) . A similar differential effect on serum insulin levels was also observed with the two guide RNAs versus control (Fig. 4d) HSL levels were significantly lower in both LDKO sgFst1
Knockdown of hepatic
AAV-TBG mice and LDKO sgFst2 AAV-TBG mice than in control (Fig. 4f,g ). The intermediate response to sgFst1 AAV-TBG infection seems to arise from its variable infection or effect on Fst levels. To confirm the relationship between circulating Fst and the biological responses, we calculated Pearson correlation coefficients for the combined groups of mice. Significant correlations were calculated in all cases: Fst versus fasting insulin: r = 0.93, P < 0.0001; Fst versus GTT-AUC (area under the curve): r = 0.763, P < 0.0001; and Fst versus PI3K: r = − 0.408, P = 0.0310. Thus, the Fst concentration measured across each group (Cntr, null, sgFst1 and sgFst2) correlated significantly with each biological response. Taken together, these results suggest that lowering hepatic Fst levels improved insulin sensitivity of the eWAT and glucose tolerance in LDKO mice.
As CRISPR-Cas9-based gene editing can produce off-target effects, we used hepatic shFst AAV-TBG infection to validate the benefit of reducing hepatic Fst mRNA levels in LDKO mice ( Supplementary  Fig. 6a ). Compared to the null AAV-TBG infection, the eWAT from LDKO shFst AAV-TBG mice displayed significantly reduced levels of hepatic and circulating Fst ( Supplementary Fig. 6b,c) , improved glucose tolerance ( Supplementary Fig. 6d ), increased Akt phosphorylation (pT308 Akt and pS473 Akt ) and decreased pS660 HSL levels ( Supplementary Fig. 6e,f) . Together, these results confirm that hepatic-derived Fst promotes glucose intolerance and insulin resistance of the eWAT in LDKO mice.
To establish the relationship between hepatic Fst and HGP, the hyperinsulinemic-euglycemic clamp was conducted on LDKO mice infected with shFst AAV-TBG or null AAV-TBG . The GIR required to maintain euglycemia was significantly greater in LDKO shFst AAV-TBG mice than in LDKO null AAV-TBG mice, suggesting that reducing hepatic Fst levels increased systemic insulin sensitivity (Fig. 4h,i) . Compared to the control LDKO null AAV-TBG mice, HGP decreased in LDKO shFst AAV-TBG mice during the insulin clamp and the suppression of HGP by insulin was restored (Fig. 4j,k) . Thus, knockdown of hepatic Fst in LDKO mice provided a benefit similar to that conferred by genetic disruption of hepatic FoxO1.
To establish whether Fst contributes to glucose intolerance in a non-genetic model of diabetes, C57BL6 mice maintained on a HFD for 2 months were infected with shFst AAV-TBG or null AAV-TBG . Serum Fst levels were 37% lower in shFst AAV-TBG mice than in the control null AAV-TBG mice (Fig. 4l) . Suppression of hepatic Fst resulted in significantly lower circulating glucose levels before and during the GTT than in control-treated mice (Fig. 4m,n) . Thus, hepatic Fst promoted glucose intolerance during genetic or physiological diabetes.
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Fst promotes WAT insulin resistance and HGP in WT mice. Next, we investigated directly whether circulating Fst in LDKO mice can dysregulate adipose insulin signaling. Cultured 3T3-L1 adipocytes were incubated with mouse serum obtained from Cntr or LDKO mice, then treated briefly with insulin. Compared with serum from Cntr mice, serum from LDKO mice resulted in significantly lower (by 37%) insulin-stimulated Irs1-p110 PI3K complex formation; moreover, the addition of an antibody to neutralize Fst in the LDKO serum resulted in greater Irs1-p110 PI3K complex formation that approached the normal range (Fig. 5a ).
To test whether Fst315 induced WAT insulin resistance in WT mice, C57BL6 mice maintained on a HFD for 4 months were infected with control GFP AAV-TBG or Fst315 Table 2 for individual data). Data were analyzed by one-way ANOVA (a,b,d), unpaired Student's t-test (e-g) and paired Student's t-test (h,i). Data are reported as the mean ± s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; NS, not significant. PI3K complex formation in eWAT, measured 2 weeks after infection (e). Insulin-regulated phosphorylation of Akt and HSL in eWAT was analyzed 2 weeks after infection by immunoblotting (f) and quantitated by densitometry (g). h-k, Five-month-old LDKO mice were infected with null AAV-TBG or shFst AAV-TBG (encoding a microRNA-like hairpin RNA against Fst) and hyperinsulinemic-euglycemic clamps were conducted 4 weeks later (n = 5). Blood glucose concentrations (h) and GIRs (i) before and at steady state during the hyperinsulinemic-euglycemic clamp. Basal and clamped HGP (j) and the calculated suppression of HGP by insulin during the clamp (k). l-n, Five-week-old C57BL6 mice maintained on a HFD for 2 months were infected with shFst AAV-TBG or null AAV-TBG (n = 7). Serum Fst levels were measured 2 weeks after infection (l); GTTs (m) and fasting blood glucose levels (n) were measured 10 days after infection. Data (b,d,e) were reported as the median ± 95% CI and the Kruskal-Wallis test was used to identify significant differences between treatments of LDKO mice. Other data are reported as the mean ± s.e.m. Data were analyzed by one-way ANOVA (a,c,g,j), two-way ANOVA (i) and unpaired Student's t-test (k-n). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Articles
NaTUre MeDiciNe clamp ( Fig. 5b-d) ; however, uptake by BAT was not affected (Fig. 5e ). Both pT308 Akt and pS473 Akt levels were significantly higher, whereas pS660
HSL levels were significantly lower in the eWAT of C57BL6 Fst315
AAV-TBG mice (Fig. 5f,g ). Unlike Fst315, Fst288 has a functional heparin-binding domain that can anchor it to the cell membrane upon secretion, where it might compete with receptors for binding to TGF-β superfamily ligands 27 . We placed C57BL6 mice on a HFD for 2 months and then infected them with , and hyperinsulinemic-euglycemic clamps were performed 4 weeks later. Uptake of 2-DOG tracer into eWAT (b), iWAT (c), skeletal muscle (d) and BAT (e), measured at the end of the clamp (n = 6). Western blot analysis (f) and densitometric quantitation (g) of insulin-regulated Akt and HSL phosphorylation in eWAT upon completion of the clamp. Blood glucose concentrations (h) and GIRs (i) before and during the hyperinsulinemic-euglycemic clamp (n = 6). Basal and clamped HGP (j) and the calculated suppression of HGP by insulin during the clamp (k) (n = 6). l, The change in serum FFA levels (the percentage of the overnight-fasted baseline) following insulin treatment (1 U per kg, intraperitoneal) of 14-week-old C57BL6 mice (maintained 10 weeks on a HFD) 2 weeks after infection with Fst315 AAV-TBG or GFP AAV-TBG (n = 10). m, The change in serum FFA levels (the percentage of the overnightfasted baseline) following insulin treatment (1 U per kg, intraperitoneal) of 4-month-old LTKO mice 2 weeks after infection with Fst315 AAV-TBG or GFP AAV-TBG (n = 6-7). n, Urinary ketone levels in 4-month-old LDKO and Cntr mice after a 5-h fast (n = 10-12). o, Urinary ketone levels (5-h fasting) in 4-month-old LTKO and Cntr3 mice 2 weeks after infection with GFP AAV-TBG or Fst315 AAV-TBG (n = 8). Data in panel a were analyzed by ANOVA and compared by BenjaminiHochberg FDR (*q < 0.05); other data were analyzed by unpaired Student's t-test (b-e,g,k,n), one-way ANOVA (j,o) and two-way ANOVA (i,l,m). Data are reported as the mean ± s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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Fst288 AAV-TBG . Four weeks later, hepatic Fst288 mRNA and protein levels were 128-fold and 4-fold higher, respectively, than in control mice ( Supplementary Fig. 7a,b) . Unexpectedly, circulating Fst levels were elevated by 12-fold 1 week after infection, indicating that hepatic Fst288 entered the circulation (Supplementary Fig. 7c ). Compared to control C57BL6 GFP AAV-TBG mice on the HFD, fasting plasma insulin and blood glucose concentrations increased significantly in C57BL6 Fst288 AAV-TBG mice ( Supplementary Fig. 7d ,e), which also developed glucose intolerance (Supplementary Fig. 7f ). Fst288
AAV-TBG infection resulted in a 2-fold lowering of 2-DOG uptake into eWAT and iWAT upon completion of the hyperinsulinemic-euglycemic clamp ( Supplementary Fig. 7g,h) .
We next conducted hyperinsulinemic-euglycemic clamps to measure HGP in C57BL6 mice infected with GFP AAV-TBG , Fst315
AAV-TBG or Fst288 AAV-TBG . On a HFD, the GIR required to maintain euglycemia during the clamp in the GFP AAV-TBG -infected mice was significantly higher than in either Fst315
AAV-TBG or Fst288 AAV-TBG mice (Fig. 5h ,i and Supplementary Fig. 7i,j) . Moreover, the hepatic expression of either Fst315 or Fst288 increased HGP during basal and clamp conditions, and strongly reduced the ability of insulin to suppress HGP (Fig. 5j,k and Supplementary Fig. 7k,l) .
Compared to fasted Cntr mice on the HFD, insulin failed to suppress circulating FFAs in fasted C57BL6 Fst315
AAV-TBG mice maintained on a HFD (Fig. 5l) . To confirm the inhibitory effect of Fst on the suppression of lipolysis, metabolically normal LTKO mice were infected with Fst315 AAV-TBG or control GFP AAV-TBG . Two weeks later, FFA levels after insulin treatment (1 U per kg) decreased normally in the Cntr mice, but only weakly in LTKO Fst315 AAV-TBG mice (Fig. 5m) . As in LDKO mice, urinary ketone levels were greater in the LTKO Fst315 AAV-TBG mice than in the Cntr mice (Fig. 5n,o) . These results are consistent with unsuppressed lipolysis owing to Fst-induced WAT insulin resistance. Fig. 8a ). Fst288
Regulation of hepatic gene expression by
AAV-TBG infection modestly upregulated or downregulated the expression of many genes, including several genes related to hepatic glucose metabolism (Pck1, G6pc and Gck) ( Supplementary  Fig. 8a ), and qPCR confirmed that Fst288 AAV-TBG affected the expression of these and other genes during both fasting (Pck1, G6pc and Gck) and feeding (Foxo1, Igfbp1, Pck1 and Ppargc1a) (Fig. 6a,b) . We also found that Fst288 expression was associated with a significant increase in glucose-6-phosphatase enzyme activity (encoded by G6pc) during fasting, which is essential for increased HGP (Fig. 6c) . Microarray analysis revealed that Fst288 modestly downregulated several lipid and cholesterol synthetic genes ( Supplementary Fig. 8a ). We used qPCR to confirm that Fst288 reduced the expression of hepatic Srebf1, Fasn and Hmgcs1 ( Supplementary Fig. 8b) ; moreover, immunoblotting showed that Fst288 AAV-TBG increased HSL and decreased Srebp1 protein levels in the C57BL6 mouse liver (Supplementary Fig. 8c ).
Hepatic FoxO1 mediates many effects of insulin on glucose and lipid metabolism 13 . To determine whether Fst288 modulates FoxO1 cellular distribution, we compared the concentration of FoxO1 in nuclear and cytoplasmic fractions of liver lysates from fasting and fed C57BL6 Fst288 mice. Compared to control C57BL6 GFP mice, the total FoxO1 protein concentration was ~2-fold greater in the liver of C57BL6 Fst288 mice (Fig. 6d) . Both nuclear and cytoplasmic FoxO1 concentrations were greater during fasting; however, during feeding, nuclear FoxO1 levels were greater, whereas cytoplasmic FoxO1 levels were lower, opposite to the regulation of FoxO1 by insulin (Fig. 6d) .
To determine whether Fst288-regulated hepatic gene expression is dependent on FoxO1, we infected LTKO mice with Fst288 AAV-TBG . RNA expression profiles showed that Fst288 regulated the expression of genes involved in gluconeogenesis and glycolysis, decreasing the expression of Gck and increasing the expression of Pck1 and G6pc, even without hepatic FoxO1; however, Fst288-mediated downregulation of lipogenic and cholesterogenic genes, such as Srebf1, was lost in the LTKO mice ( Supplementary Fig. 8a ). Next, to determine whether Fst288 required hepatic FoxO1 to promote HGP, GTTs and hyperinsulinemic-euglycemic clamps were performed. Compared to control GFP AAV-TBG LTKO mice, glucose tolerance was impaired mildly in Fst288 AAV-TBG LTKO mice (Fig. 6e) . The GIR required to maintain euglycemia during the clamp was also much less in Fst288
AAV-TBG LTKO mice than in GFP AAV-TBG LTKO mice (Fig. 6f,g ). As in LDKO mice, insulin failed to suppress HGP in the Fst288 AAV-TBG LTKO mice (Fig. 6h,i) ; thus, the detrimental effect of Fst288 on HGP developed without hepatic FoxO1.
Fst-mediated WAT insulin resistance is independent of hepatic FoxO1. Finally, we investigated whether reduced Fst levels in LTKO mice contributed to their improved glucose tolerance and eWAT insulin sensitivity. We infected LTKO mice with Fst315
AAV-TBG to increase circulating Fst315 levels by about ninefold ( Supplementary  Fig. 9a ). Compared to control GFP AAV-TBG LTKO mice, the LTKO Fst315 AAV-TBG mice developed profound glucose intolerance that phenocopied LDKO mice ( Supplementary Fig. 9b ). During insulin stimulation, both pT308
Akt and pS473 Akt levels decreased significantly-and pS660
HSL levels increased significantly-in the eWAT of LTKO Fst315
AAV-TBG mice ( Supplementary Fig. 9c,d ). These results suggested that Fst315 promoted WAT insulin resistance independently of hepatic FoxO1. Moreover, the GIR required to achieve euglycemia decreased in clamped LTKO Fst315 AAV-TBG mice ( Supplementary Fig. 9e,f) , and insulin failed to suppress HGP in LTKO Fst315
AAV-TBG mice compared to LTKO GFP AAV-TBG mice ( Supplementary Fig. 9g,h) . Thus, FoxO1-dependent glucose dysregulation in LDKO mice is due, at least in part, to FoxO1-dependent upregulation of Fst, rather than hepatic FoxO1 alone.
Discussion
Our results identify the hepatokine Fst as a mediator of systemic metabolic dysregulation driven by hepatic FoxO1 activity. Previous investigations have highlighted the FoxO1-dependent nature of excessive HGP and/or glucose intolerance in mice with hepatic insulin resistance 12, 15, 18 . We previously showed that insulin fails to suppress HGP in our LDKO mice 14 ; herein, we confirm that HGP suppression is restored in LDKO mice by disruption of hepatic FoxO1 (LTKO mice). Correlating with HGP, the expression and secretion of Fst are strongly upregulated in the LDKO liver but are nearly normalized in the LTKO liver. Within primary hepatocytes, knockdown of FoxO1 decreases-and its overexpression increases-the expression and secretion of Fst. Comparable with the direct regulation by FoxO1, we observe enriched recovery of Fst promoter regions containing FoxO1-binding motifs in anti-FoxO1 chromatin immunoprecipitates. Importantly, reducing hepatic production of Fst in LDKO mice using CRISPR-Cas9 or Fst shRNA mimics the benefits of Foxo1 deletion in LTKO mice. Conversely, viral expression of Fst in the liver of high-fat-fed WT mice or chowfed LTKO mice reproduces an LDKO-like phenotype, including impaired WAT insulin sensitivity, unsuppressed HGP and severe glucose intolerance. Thus, reduced expression and secretion of Fst may largely explain the restoration of metabolic homeostasis in LTKO versus LDKO mice 12 . Nonetheless, we do not rule out that other liver-intrinsic factors might contribute, particularly as viral expression of Fst alters RNA expression profiles in the livers of both WT and LTKO mice.
Although HGP and glucose tolerance are normalized in LTKO mice, the IRS-PI3K-Akt cascade in the liver of LTKO mice remains insensitive to insulin 12 . Our data support that normalization of Articles NaTUre MeDiciNe HGP in LTKO mice (and similar models) owes substantially to the restoration of WAT insulin sensitivity, which reduces lipolysis and the availability of FFAs and glycerol that potentiate hepatic gluconeogenesis 1, 16, 17 . Demonstrating the negative influence of hepatic FoxO1 on WAT insulin sensitivity, we observed significantly impaired IRK-IRS-Akt signaling and Akt-PDE3B-HSL signaling in the LDKO WAT, as well as impaired insulin suppression of serum FFAs-each of which is normalized in LTKO mice. . Hepatic mRNA expression was measured by qPCR after a 16-h overnight fast without (a) or with 4-h refeeding (b) 1 week after AAV infection. Glucose-6-phosphatase (G6PC) activity after a 16-h overnight fast in the liver 1 week after infection with Fst288 AAV-TBG or GFP AAV-TBG (n = 5) (c). Western blot analysis and densitometric quantitation of FoxO1 protein in nuclear and cytoplasmic fractions or in the total liver lysate of C57BL6 mice, with or without 4-h refeeding following a 16-h overnight fast, and 1 week after infection with Fst288 AAV-TBG or GFP AAV-TBG (n = 5) (d). e-i, Two-month-old LTKO mice were infected with GFP AAV-TBG or Fst288 AAV-TBG to reconstitute hepatic Fst. GTTs were performed 2 weeks after AAV infection (n = 7) (e). Hyperinsulinemic-euglycemic clamps were conducted 4 weeks after infection; shown are the blood glucose concentrations (f) and the GIRs before and at steady state (g) during the hyperinsulinemic-euglycemic clamp (n = 5). Basal and clamped HGP (h) and the calculated suppression of HGP by insulin during the clamp (i) (n = 5). Data were analyzed by unpaired Student's t-test (a-e,g,i) and one-way ANOVA (h). Data are reported as the mean ± s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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Within the insulin-resistant liver, excess FFAs are oxidized to acetyl-CoA and further metabolized to produce ketone bodies 28 . Our observation of elevated levels of urinary ketones in LDKO mice-but not LTKO mice-validates the oxidation of excess FFAs in the LDKO liver to acetyl-CoA, which allosterically upregulates pyruvate carboxylase-dependent hepatic gluconeogenesis and HGP 1 . Forced expression of Fst in the LTKO liver likewise increases ketone production, in conjunction with impaired suppression of HGP and glucose intolerance. Together, these data support that WAT insulin resistance mediated by Fst contributes significantly to glucose intolerance in LDKO mice 12, [29] [30] [31] ; however, additional secreted or non-secreted hepatic gene products regulated by FoxO1 might combine with Fst to produce the systemic effects of severe hepatic insulin resistance (for example, patatin-like phospholipase domain containing 2 (Pnpla2) and G0/G1 switch 2 (G0S2) 32 . Two Fst isoforms are produced by alternative mRNA splicing: membrane-bound (autocrine/paracrine) Fst288, which contains a functional heparin-binding site, and the longer circulating Fst315, which does not 21, 27, 33 . Although our assays distinguish the hepatic mRNAs encoding these isoforms, available immunoassays cannot distinguish the protein isoforms. Both Fst288 and Fst315 mRNAs are upregulated in LDKO versus control or LTKO mice. Although its heparin-binding domain reportedly anchors Fst288 to cell membranes where it is produced 27 , infection with either Fst288 AAV-TBG or Fst315
AAV-TBG increased circulating Fst levels in LTKO mice that weakly expressed endogenous Fst; moreover, the two isoforms equivalently dysregulated WAT insulin sensitivity, HGP and glucose tolerance. Regardless, mice engineered to produce only Fst288-without circulating Fst315-were shown by others to have mildly decreased fasting glucose levels 34 . We conclude that its overexpression in Fst288 AAV-TBG -infected mice confers hepatokine/endocrine function on normally autocrine/paracrine Fst288.
Fst was identified originally as a soluble protein in follicular fluid that suppresses the biosynthesis and release of follicle-stimulating hormone from the pituitary 35 . However, Fst binds to and neutralizes diverse TGF-β superfamily ligands. TGF-β superfamily signaling is initiated by heterotetrameric receptor serine kinases, composed of 'type II' and 'type I' receptors that establish the binding specificity and selective phosphorylation of R-Smads. Smad2 and Smad3 are downstream of TGF-β -activin-Nodal receptors, whereas Smad1, Smad5 and Smad8 lie downstream of the bone morphogenetic protein (BMP)-growth differentiation factor (GDF) pathway. These phosphorylated Smads assemble with Smad4 to enter the nucleus and modulate gene expression 20, 36, 37 . Fst isoforms bind primarily to activin A and activin B, myostatin (also known as GDF8), and with lower affinity to BMP4 and BMP11 (refs 27, 34, 38, 39 ). Circulating Fst-like 3 (Fstl3) binds to the same ligands as Fst 40 , and deletion of Fstl3 improves glucose tolerance in mice 41 . Neutralization of activin B might be relevant for the production of WAT insulin resistance, as it has been shown to suppress lipolysis in mouse embryo fibroblastderived adipocytes and human adipocytes 42 . However, as Fst is an inhibitor of TGF-β superfamily ligands, its activity on cultured adipocytes might depend on the mix of TGF-β ligands present in the medium. Moreover, BMP4 was shown to suppress lipolysis in preadipocytes by inhibiting HSL 43 . Neutralization of other ligands of the TGF-β superfamily receptor Acvr2b could also be involved, as a soluble form of this receptor enhances gluconeogenesis in insulininsufficient mice 44 . Future assessment of changes in WAT mRNA transcription caused by ectopic Fst and/or TGF-β superfamily ligands would aid in validating the mechanism by which Fst impairs WAT insulin sensitivity. Along these lines, we observed that virus-mediated Fst288 expression significantly alters the pattern of hepatic gene expression in high-fat-fed WT mice. As Fst expression produces a different pattern of hepatic gene expression in the LTKO liver, we suggest, provisionally, that excess circulating Fst may amplify, or alter, FoxO1-dependent hepatic gene expression changes. Regardless, as viral expression of Fst does not require hepatic FoxO1 to produce an LDKO-like phenotype (that is, in LTKO mice), Fst-induced changes in hepatic gene expression might be less critical for systemic dysregulation than its ability to promote WAT insulin resistance 45 . Previously, it was reported that insulin-resistant individuals and those with T2D exhibit modestly increased circulating Fst, and that this increase correlates positively with the percentage of HbA1c, fasting blood glucose, and glucose excursion during oral GTT 26 . Although we did not measure circulating Fst levels in healthy controls, we found that RYGB significantly reduced circulating Fst levels in obese individuals with diabetes, and that this reduction correlated with the reduced percentage of HbA1c, an indicator of improved medium-term glycemic control. Thus, an unknown therapeutic aspect of RYGB might be to reduce the effect of circulating Fst on WAT, thereby facilitating control of HGP and glycemia. Although other interpretations of these data are possible, our mouse data support the notion that targeting hepatically produced and secreted Fst in diabetic adults might prove useful in restoring systemic metabolic homeostasis. Because of its clear relation to hepatic insulin resistance and possible pleiotropic effects, targeting excess circulating Fst might also prove more fruitful than attempts to upregulate TGF-β superfamily-mediated signals in the insulinresistant WAT.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0048-0.
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Methods
Mice. We generated the liver-specific Irs1 and Irs2 double knockout (LDKO) and the Irs1, Irs2 and FoxO1 triple knockout (LTKO) mice as previously described 12, 13 . We purchased C57BL6 mice (stock no. 000664), ob/ob mice (stock no. 000632), B6.129S2-Il6tm1Kopf/J mice (stock no. 002650) and B6;FVB-Tg(AdipoqCre)1Evdr/J mice (stock no. 010803) from the Jackson Laboratory. We generated FDKO mice by crossing B6;FVB-Tg(Adipoq-Cre)1Evdr/J with Irs1 and Irs2 double floxed mice. We generated LDKO IL-6 -/-mice by crossing B6.129S2-Il6tm1Kopf/J with LDKO mice. All mice were housed in plastic cages on a 12 h/12 h light-dark cycle with free access to water and food. We performed animal experiments according to all relevant ethical regulations, and protocols were approved by the Boston Children's Hospital Institutional Animal Care and Use Committee.
Hyperinsulinemic-euglycemic clamp in conscious and unrestrained mice. Prior to the clamp experiment, one catheter was inserted into the right jugular vein for infusions. After 5-7 days of recovery, mice that had lost < 10% of their preoperative weight were subjected to the clamp. On the day of the experiment, mice were deprived of food for 3. ) at a rate of 2 µ l min -1 throughout the clamp experiment. The insulin solutions were prepared with 3% BSA in 0.9% saline. Glucose (20%) was infused at variable rates as needed to maintain plasma glucose at ~130 mg dl -1 (except in Fig. 1d ,f (Cntr ± s.e.m.: 138 ± 9 mg dl -1 ; LDKO ± s.e.m.: 204 ± 21 mg dl -1 ; P < 0.05)). All infusions were done using microinfusion pumps (KD Scientific). Blood glucose concentrations were monitored regularly according to a fixed scheme from the tail vein. To estimate insulin-stimulated glucose uptake in the WAT, BAT and skeletal muscle, 2-DOG (10 μ Ci per mice; PerkinElmer) was administered as a bolus at 95 min after the start of the clamp. Blood samples (20 µ l) were taken at − 5, 100, 110, 120, 130 and 140 min of the clamp for the measurement of plasma d- [3- 3 H]-glucose and 2-DOG concentrations. The steady-state level was considered achieved during 100-140 min, when a fixed GIR maintained the glucose concentration in the blood constantly for 40 min (see Supplementary  Fig. 12 ). At the end of the experiment, mice were killed by ketamine/xylazine and the WAT, BAT, skeletal muscle and liver were dissected and store at − 80 °C until further analysis.
The d- H]-glucose and 2-DOG concentrations in the plasma were measured according to the procedure of "Glucose Clamping The Conscious Mouse" from the Vanderbilt-NIDDK Mouse Metabolic Phenotyping Center with some modifications. Briefly, 6 μ l of plasma sample mixed with 14 μ l saline was treated with 100 µ l 3N Ba(OH) 2 and ZnSO 4 (add Ba(OH) 2 before ZnSO 4 ), and 100 μ l of supernatant was pipetted into a scintillation vial and dried in the oven overnight; 8 ml of scintillation fluid was added to the dried vial or to 50 μ l non-dry supernatant for measuring the radioactivity in a liquid scintillation counter. For measuring 2-DOG, lysates of adipose tissue and skeletal muscle were processed using a perchloric acid Ba(OH) 2 /ZnSO 4 precipitation 46 . Glucose uptake into WAT, BAT and skeletal muscle in vivo was calculated based on 2-DOG accumulation and the specific activity of 2-DOG in the serum.
HFD treatment.
Wild-type C57BL6 male mice were fed with a HFD (Research Diet: R1245i, 45 kcal (%) from fat) for 8-16 weeks.
GTTs. For GTTs, mice were fasted, but with free access to water, for 5 h before the procedure. At the start of the procedure, the mice were weighed and basal glucose levels were measured. The mice were then injected intraperitoneally with glucose (2 g per kg body weight) 6 h after fasting. Glucose levels were measured again at 15, 30, 60 and 120 min after injection.
Insulin tolerance test.
For the insulin tolerance test, mice were fasted, but with free access to water, for 4 h before the procedure. At the start of the procedure, the mice were weighed and basal glucose levels were measured. The mice were then injected intraperitoneally with human insulin (1 U per kg body weight, Humulin, Eli Lilly) 5 h after fasting. Glucose levels were measured again at 15, 30 and 60 min after injection.
Fasting/refeeding experiment. Mice were fasted, but with free access to water, for 16 h overnight and then fed with a regular chow diet for 4 h. Mice were killed after they were anesthetized with ketamine/xylazine and the liver and serum were collected for further analysis.
Insulin treatment. In vivo insulin signaling was analyzed 5 min after insulin injection of 1 U per kg human insulin via the vena cava after mice were fasted for 16 h overnight and anesthetized with ketamine/xylazine. Mice were killed and the skeletal muscle tissue, eWAT, iWAT, BAT and liver tissue were immediately frozen in liquid nitrogen for further analysis.
Blood chemistry analysis. We used commercial ELISA kits to measure circulating insulin and Fst levels according to the manufacturer's instructions. The insulin kit (80-INSMSU-E01) was purchased from Alpco Inc. Fst protein levels were measured using the human Follistatin ELISA kit (DFN00, R&D Systems; 22% cross-reactivity with mouse Fst) following the manufacturer's protocols with some modification. In brief, we applied 150 μ l mouse serum (150 μ l versus 100 μ l) and increased the incubation time (overnight versus 2 h). IL-6 protein levels were measured using Mouse IL-6 ELISA Kit (Thermo Scientific Pierce, EM2IL6). The blood glucose level was measured using a glucose meter (Bayer Contour). Urine ketone bodies were measured using commercial assay kits (415-73301 and 411-73401, Wako USA). Serum IL-1β , IL-2, IL-4, IL-5, KC and MIP1-α concentrations were measured using Milliplex MAP mouse magnetic bead panel kit.
Primary hepatocytes isolation. Eight-to-ten-week-old mice were anesthetized by intraperitoneal injection of ketamine/xylazine (100 mg per kg and 10 mg per kg body weight). Following anesthesia, the abdominal cavity was opened by incisions with scissors and the vena cava and portal vein were located. A perfusion catheter was placed into the vena cava. Pre-warmed Liver Perfusion Medium (17701, Invitrogen) (37 °C) was delivered at 1.6 ml min -1 for 12 min using a peristaltic pump. An incision was made at the portal vein as an outlet for the perfusion solution. Immediately following the Liver Perfusion Medium, pre-warmed Liver Digest Medium (17703, Invitrogen) (37 °C) was delivered at 1.6 ml min -1 for 12 min using a peristaltic pump. At the end of the perfusion, the liver was dissected and transferred to a Petri dish on ice containing 10 ml L-15 medium (21083, Invitrogen) with 10% FBS. After washing three times with Hepatocyte Wash Buffer (17704, Invitrogen), the primary hepatocytes were re-suspended in William's E medium (12551, Invitrogen) containing Percoll beads (p4937, Sigma). After 4 h of incubation in William's E medium containing 10% FBS and penicillin-streptomycin, the unattached cells were removed and the dishes were washed with PBS and incubated with maintenance media (William's E medium containing 100 μ M Dex, insulin-transferrin-selenium, 2 mM glutamine and PenStrep).
3T3-L1 cell culture. 3T3-L1 pre-adipocytes obtained from a mycoplasma-free stock were cultured in DMEM/F12 with 10% BCS in 5% CO 2 . Two days postconfluence, cells were exposed to DMEM/10% FBS with isobutylmethylxanthine (0.5 mM), dexamethasone (1 μ M) and insulin (5 μ g ml -1 ). After 2 days, cells were maintained in DMEM/10% FBS until ready for treatment at day 7. On day 9, cells were treated with insulin (10 nM) for 3 min after being maintained in DMEM/5% mouse serum for 24 h. Luminex assays. As described previously 47, 48 , the Irs1 capture antibody (rabbit monoclonal antibody 58-10C-31, catalogue number 05-784R, Millipore) was coupled to magnetic carboxylated microspheres. The p110 subunit of PI3K was detected with antibodies from Cell Signaling Technology (4249). For Luminex assays, cell lysates (10 μ g) or mouse tissue lysates (80 μ g) were diluted with Irs1 capture beads (4,000 beads per well) into a total volume of 50 μ l of phosphoprotein detection wash buffer (Bio-Rad) and incubated overnight in 96-well round-bottom plates. After washing twice with the same buffer, the beads were incubated with 50 μ l detection antibody for 1 h on a rotary plate shaker (80 r.p.m.). After removal of the biotinylated detection antibody, the beads were incubated with shaking in 25 μ l of 1 μ g ml -1 streptavidin-phycoerythrin (Prozyme) for 15 min. All solutions were then removed and beads were suspended in PBS-BN (Sigma) for analysis in a Luminex FlexMap 3D instrument.
Histological and immunohistochemical analyses. The liver and WAT were fixed in phosphate-buffered paraformaldehyde (10%) and embedded in paraffin. H&E staining was conducted by the Pathology Core in the Dana-Farber Harvard Cancer Center. Fst immunostaining was conducted as described previously 2 . To probe Fst in the liver sections, tissues were deparaffinized in xylene and rehydrated in a series of alcohol/water mixtures. Antigen retrieval was performed in 10 mM sodium citrate, pH 6.0, for 10 min. Tissue sections were blocked in 10% normal goat serum, incubated with the primary antibodies (203131, Abcam) overnight at 4 °C and with goat anti-rabbit secondary antibody (A11012, Molecular Probes) for 1 h at room temperature (25 °C). Slide mounting was performed using Prolong Antifade Gold with DAPI (1652731, Life Technologies). Composite images were created from a 10 × 10 array of adjacent non-overlapping × 10 magnification images taken using a Zeiss Axiovert LSM 510 microscope.
Nuclear and cytoplasmic protein extraction. The nuclear and cytoplasmic proteins were differentially extracted as directed using a kit from Thermo Scientific (NE-PER Nuclear and Cytoplasmic Extraction Kit, 78835).
G6Pase activity measurement. G6Pase activity assays were performed as previously described 49 . Briefly, 100 mg liver was homogenized in buffer (HEPES, 5 mM; sucrose, 250 mM) using a dounce homogenizer. Microsomes were prepared using ultracentrifuge at 100,000g. The reaction was started by adding microsomes into the substrates mix (G6P, 1-5 mM; sodium cacodylate,183.3 mM; histone type IIA, 10 mg ml -1 ). Absorbance was measured at 820 nm. 
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